专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08916552B2 Pharmaceutical combinations 有权
标题翻译：药物组合
公开(公告)号：US08916552B2
公开(公告)日：2014-12-23
申请号：US12445180
申请日：2007-10-12
申请人： Neil James Gallagher , John Francis Lyons , Neil Thomas Thompson , Stephen Murray Yule , Christopher William Murray
发明人： Neil James Gallagher , John Francis Lyons , Neil Thomas Thompson , Stephen Murray Yule , Christopher William Murray
IPC分类号： A61K31/535 , A61K31/497 , A01N43/40 , A61K31/435 , A61K31/445 , A01N43/56 , A61K31/415 , A01N43/38 , A61K31/40 , C07D209/44 , A61K45/06 , A61K31/4035 , A61K31/403
CPC分类号： A61K31/403 , A61K31/4035 , A61K45/06 , A61K2300/00
摘要： The invention provides combinations comprising (or consisting essentially of) one or more ancillary compound(s) and a compound of the formula (I): or salts, tautomers, solvates and N-oxides thereof; wherein R1 is hydroxy or hydrogen; R2 is hydroxy; methoxy or hydrogen; provided that at least one of R1 and R2 is hydroxy; R3 is selected from hydrogen; halogen; cyano; optionally substituted C1-5 hydrocarbyl and optionally substituted C1-5 hydrocarbyloxy; R4 is selected from hydrogen; a group —(O)n—R7 where n is 0 or 1 and R7 is an optionally substituted acyclic C1-5 hydrocarbyl group or a monocyclic carbocyclic or heterocyclic group having 3 to 7 ring members; halogen; cyano; hydroxy; amino; and optionally substituted mono- or di-C1-5 hydrocarbyl-amino; or R3 and R4 together form a monocyclic carbocyclic or heterocyclic ring of 5 to 7 ring members; and NR5R6 forms an optionally substituted bicyclic heterocyclic group having 8 to 12 ring members of which up to 5 ring members are heteroatoms selected from oxygen, nitrogen and sulphur. The combinations have activity as Hsp90 and/or glycogen synthase kinase-3 and/or cyclin dependent kinase inhibitors.
摘要翻译：本发明提供包含（或基本上由）一种或多种辅助化合物和式（I）化合物或其盐，互变异构体，溶剂合物和N-氧化物的组合; 其中R1是羟基或氢; R2是羟基; 甲氧基或氢; 条件是R 1和R 2中的至少一个是羟基; R3选自氢; 卤素; 氰基; 任选取代的C 1-5烃基和任意取代的C 1-5烃氧基; R4选自氢; 其中n为0或1，R7为任选取代的无环C 1-5烃基或具有3至7个环成员的单环碳环或杂环基团 - （O）n -R 7基团; 卤素; 氰基; 羟基; 氨基; 和任选取代的单或二-C 1-5烃基 - 氨基; 或R 3和R 4一起形成5至7个环成员的单环碳环或杂环; 并且NR 5 R 6形成具有8至12个环成员的任选取代的双环杂环基，其中多达5个环成员是选自氧，氮和硫的杂原子。这些组合具有作为Hsp90和/或糖原合酶激酶-3和/或细胞周期蛋白依赖性激酶抑制剂的活性。

2. 发明授权

US08779132B2 Pharmaceutical compounds 失效
标题翻译：药物化合物
公开(公告)号：US08779132B2
公开(公告)日：2014-07-15
申请号：US12445154
申请日：2007-10-12
申请人： Miles Stuart Congreve , Lynsey Helen Fazal , Martyn Frederickson , Christopher William Murray , Michael Alistair O'Brien , Andrew James Woodhead , John Francis Lyons , Neil Thomas Thompson
发明人： Miles Stuart Congreve , Lynsey Helen Fazal , Martyn Frederickson , Christopher William Murray , Michael Alistair O'Brien , Andrew James Woodhead , John Francis Lyons , Neil Thomas Thompson
IPC分类号： C07D403/06 , A61K31/497
CPC分类号： C07D403/06 , C07D209/08 , C07D209/44 , C07D215/08 , C07D215/14 , C07D217/06 , C07D401/04 , C07D401/12 , C07D401/14 , C07D471/04 , C07D471/08 , C07D471/10 , C07D491/08 , C07D491/10 , C07D491/107 , C07D491/18
摘要： The invention provides a compound for use in medicine, the compound being a compound of the formula (VI0) or a salt, solvate, tautomer or N-oxide thereof: wherein the bicyclic group: is selected from the structures C1, C5 and C6: wherein n is 0, 1, 2 or 3; R1 is hydrogen, hydroxy, or O—Rz; R2a is hydroxy, methoxy or O—Rz; provided that at least one of R1 and R2a is O—Rz; Rz is Lp-Rp1; SO3H; a glucuronide residue; a mono-, di- or tripeptide residue; or Lp is a bond, C═O, (C═O)O, (C═O)NRp1 or S(O)xNRp1; x is 1 or 2; Rp1 is hydrogen or a an optionally substituted C1-25 hydrocarbyl group containing 0, 1 or 2 carbocyclic rings and 0, 1, 2, 3, 4, 5 or 6 carbon-carbon multiple bonds, provided that Rp1 is not hydrogen when Lp is a bond, C═O or (C═O)O; and provided also that O—Rz does not contain an O—O moiety; and excluding compounds wherein R1 is hydroxy and R2a is methoxy; Rp2 and Rp3 are the same or different and each is a group Rp1; and R3, R4a, R8 and R10 are defined in the claims. The compounds of formula (VI0) are pro-drugs of parent compounds wherein R1 and/or R2a are hydroxy, wherein the parent compounds have Hsp90 inhibiting activity.
摘要翻译：本发明提供了一种用于医药的化合物，该化合物为式（VI0）化合物或其盐，溶剂化物，互变异构体或N-氧化物：其中双环基团：选自结构C1，C5和C6：其中n为0,1,2或3; R1是氢，羟基或O-Rz; R2a是羟基，甲氧基或O-Rz; 条件是R1和R2a中的至少一个是O-Rz; Rz是Lp-Rp1; SO3H; 葡萄糖苷酸残基; 单，二或三肽残基; 或Lp为键，C = O，（C = O）O，（C = O）NRp1或S（O）xNRp1; x为1或2; Rp1是氢或任选取代的含有0,1或2个碳环和0,1,2,3,4,5或6个碳 - 碳多重键的C1〜25烃基，条件是当Lp为一个键，C = O或（C = O）O; 并且还提供O-Rz不含有O-O部分; 并且不包括其中R 1是羟基并且R 2a是甲氧基的化合物; Rp2和Rp3相同或不同，并且各自为基团Rp1; R3，R4a，R8和R10如权利要求中所定义。式（VI0）化合物是其中R 1和/或R 2a是羟基的母体化合物的前药，其中母体化合物具有Hsp90抑制活性。

3. 发明授权

US08399442B2 Pharmaceutical compounds 失效
标题翻译：药物化合物
公开(公告)号：US08399442B2
公开(公告)日：2013-03-19
申请号：US12159054
申请日：2006-12-29
申请人： Valerio Berdini , Jayne Elizabeth Curry , Neil James Gallagher , Adrian Liam Gill , John Francis Lyons
发明人： Valerio Berdini , Jayne Elizabeth Curry , Neil James Gallagher , Adrian Liam Gill , John Francis Lyons
IPC分类号： A61K31/33
CPC分类号： C07D403/04 , A61K31/4155 , A61K31/4184 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D487/04 , C07D491/056 , C07D513/04
摘要： A method for the treatment of: A. a disease state or condition mediated by a kinase wh ich is BCR-abl, VEGFR, PDGFR, EGFR, FLT3, JAK, C-abl, PDK1, Chk, FGFR, Ret, Eph, or Src; or B. a cancer in which the cancer cells thereof contain a drug resistant kinase mutation which is: (a) a threonine gatekeeper mutation; or (b) a drug-resistant gatekeeper mutation; or (c) an imatinib resistant mutation; or (d) a nilotinib resistant mutation; or (e) a dasatinib resistant mutation; or (f) a T670l mutation in KIT; or (g) a T674l mutation in PDGFR; or (h) T790M mutation in EGFR; or (i) a T315l mutation in abl; or C. a cancer which expresses a mutated molecular target which is a mutated form of BCRabl, c-kit, PDGF, EGF receptor or ErbB2; which method comprises administering to a patient in need thereof a therapeutically effective amount of a compound of the formula (l or l′): or a salt, solvate, tautomer or N-oxide thereof.
摘要翻译：一种治疗以下疾病的方法：A.由BCR-abl，VEGFR，PDGFR，EGFR，FLT3，JAK，C-abl，PDK1，Chk，FGFR，Ret，Eph或 Src 或B.一种其癌细胞含有耐药性激酶突变的癌症，其为：（a）苏氨酸关守突变; 或（b）耐药性守门人突变; 或（c）伊马替尼耐药突变; 或（d）尼洛替尼耐药突变; 或（e）达沙替尼抗性突变; 或（f）KIT中的T6701突变; 或（g）PDGFR中的T674l突变; 或（h）EGFR中的T790M突变; 或（i）abl中的T3151突变; 或C.表达突变形式的BCRab1，c-kit，PDGF，EGF受体或ErbB2的突变分子靶的癌症; 该方法包括向有需要的患者施用治疗有效量的式（I或1'）化合物或其盐，溶剂化物，互变异构体或N-氧化物。

4. 发明申请

US20100152184A1 PHARMACEUTICAL COMPOUNDS 失效
标题翻译：药物化合物
公开(公告)号：US20100152184A1
公开(公告)日：2010-06-17
申请号：US12445154
申请日：2007-10-12
申请人： Miles Stuart Congreve , Lynsey Helen Fazal , Martyn Frederickson , Christopher William Murray , Michael Alistair O'Brien , Andrew James Woodhead , John Francis Lyons , Neil Thomas Thompson
发明人： Miles Stuart Congreve , Lynsey Helen Fazal , Martyn Frederickson , Christopher William Murray , Michael Alistair O'Brien , Andrew James Woodhead , John Francis Lyons , Neil Thomas Thompson
IPC分类号： A61K31/5377 , C07D209/44 , C07D215/14 , C07D221/20 , C07D471/04 , C07D403/10 , C07D413/12 , A61K31/4035 , A61K31/47 , A61K31/438 , A61K31/497 , A61P35/00
CPC分类号： C07D403/06 , C07D209/08 , C07D209/44 , C07D215/08 , C07D215/14 , C07D217/06 , C07D401/04 , C07D401/12 , C07D401/14 , C07D471/04 , C07D471/08 , C07D471/10 , C07D491/08 , C07D491/10 , C07D491/107 , C07D491/18
摘要： The invention provides a compound for use in medicine, the compound being a compound of the formula (VI0) or a salt, solvate, tautomer or N-oxide thereof: wherein the bicyclic group: is selected from the structures C1, C5 and C6: wherein n is 0, 1, 2 or 3; R1 is hydrogen, hydroxy, or O—Rz; R2a is hydroxy, methoxy or O—Rz; provided that at least one of R1 and R2a is O—Rz; Rz is Lp-Rp1; SO3H; a glucuronide residue; a mono-, di- or tripeptide residue; or Lp is a bond, C═O, (C═O)O, (C═O)NRp1 or S(O)xNRp1; x is 1 or 2; Rp1 is hydrogen or a an optionally substituted C1-25 hydrocarbyl group containing 0, 1 or 2 carbocyclic rings and 0, 1, 2, 3, 4, 5 or 6 carbon-carbon multiple bonds, provided that Rp1 is not hydrogen when Lp is a bond, C═O or (C═O)O; and provided also that O—Rz does not contain an O—O moiety; and excluding compounds wherein R1 is hydroxy and R2a is methoxy; Rp2 and Rp3 are the same or different and each is a group Rp1; and R3, R4a, R8 and R10 are defined in the claims.The compounds of formula (VI0) are pro-drugs of parent compounds wherein R1 and/or R2a are hydroxy, wherein the parent compounds have Hsp90 inhibiting activity.
摘要翻译：本发明提供了一种用于医药的化合物，该化合物为式（VI0）化合物或其盐，溶剂化物，互变异构体或N-氧化物：其中双环基团：选自结构C1，C5和C6：其中n为0,1,2或3; R1是氢，羟基或O-Rz; R2a是羟基，甲氧基或O-Rz; 条件是R1和R2a中的至少一个是O-Rz; Rz是Lp-Rp1; SO3H; 葡萄糖苷酸残基; 单，二或三肽残基; 或Lp为键，C = O，（C = O）O，（C = O）NRp1或S（O）xNRp1; x为1或2; Rp1是氢或任选取代的含有0,1或2个碳环和0,1,2,3,4,5或6个碳 - 碳多重键的C1〜25烃基，条件是当Lp为一个键，C = O或（C = O）O; 并且还提供O-Rz不含有O-O部分; 并且不包括其中R 1是羟基并且R 2a是甲氧基的化合物; Rp2和Rp3相同或不同，并且各自为基团Rp1; R3，R4a，R8和R10如权利要求中所定义。式（VI0）化合物是其中R 1和/或R 2a是羟基的母体化合物的前药，其中母体化合物具有Hsp90抑制活性。

5. 发明申请

US20100055094A1 PHARMACEUTICAL COMBINATIONS OF 1-CYCLOPROPYL-3- [3-(5-M0RPHOOLIN-4-YL-METHYL-1H-BENZOIMIDAZOL-2-YL)- LH-1-PYRAZOL-4-YL]- UREA 失效
标题翻译： 1-环丙基-3- [3-（5-M0RPHOOLIN-4-YL-甲基-1H-苯并咪唑-2-基）-LH-1-吡唑-4-基] - 尿素的药物组合
公开(公告)号：US20100055094A1
公开(公告)日：2010-03-04
申请号：US12306479
申请日：2007-06-29
申请人： Jayne Elizabeth Curry , Neil James Gallagher , John Francis Lyons , Neil Thomas Thompson
发明人： Jayne Elizabeth Curry , Neil James Gallagher , John Francis Lyons , Neil Thomas Thompson
IPC分类号： A61K31/4184 , A61K31/5377 , A61K31/4353 , A61K31/4439 , A61K31/454 , A61K31/52 , A61K39/395 , A61K31/56 , A61K33/24 , A61P35/04
CPC分类号： A61K45/06 , A61K31/337 , A61K31/475 , A61K31/5377 , A61K31/7072 , A61K33/24 , A61K2300/00
摘要： The invention provides combinations of an ancillary compound and a compound which is a salt of 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea selected from the lactate and citrate salts and mixtures thereof. Also provided are crystalline forms of the salts, methods for making the salts and their uses in treating cancers. The invention further provides combinations of an ancillary compound and a compound of the formula (I) as defined in PCT/GB2004/002824 (WO 2005/002552) or a compound of the formula (I′) or a salt, solvate, tautomer or N-oxide thereof, wherein R1, E, A and M are as defined in the claims.
摘要翻译：本发明提供了辅助化合物和化合物的组合，其是1-环丙基-3- [3-（5-吗啉-4-基甲基-1H-苯并咪唑-2-基）-1H-吡唑-4-基 ] - 选自乳酸盐和柠檬酸盐及其混合物。还提供盐的结晶形式，制备盐的方法及其在治疗癌症中的用途。本发明还提供了辅助化合物和如PCT / GB2004 / 002824（WO 2005/002552）中定义的式（I）化合物或式（I'）化合物或其盐，溶剂合物，互变异构体或其中R1，E，A和M如权利要求中所定义。

6. 发明申请

US20090263398A1 PHARMACEUTICAL COMBINATIONS 审中-公开
标题翻译：药物组合
公开(公告)号：US20090263398A1
公开(公告)日：2009-10-22
申请号：US12373713
申请日：2007-07-13
申请人： John Francis Lyons , Matthew Simon Squires , Neil Thomas Thompson , Neil James Gallagher , Jayne Elizabeth Curry
发明人： John Francis Lyons , Matthew Simon Squires , Neil Thomas Thompson , Neil James Gallagher , Jayne Elizabeth Curry
IPC分类号： A61K31/415 , A61K31/422 , A61K31/4178 , A61K31/4155 , A61K31/4439 , A61K31/496 , A61K31/5377 , A61K31/454 , A61K31/506 , A61K31/541 , A61K31/439 , A61P35/00 , A61K39/395
CPC分类号： A61K31/4453 , A61K31/415 , A61K2300/00
摘要： The invention provides a combination comprising an ancillary compound and a compound having the formula (0): or salts or tautomers or N-oxides or solvates thereof; wherein X is a group R1-A-NR4— or a 5- or 6-membered carbocyclic or heterocyclic ring; A is a bond, SO2, C═O, NR9(C═O) or 0(C═O) wherein R9 is hydrogen or C1-4 hydrocarbyl optionally substituted by hydroxy or C1-4 alkoxy; Y is a bond or an alkylene chain of 1, 2 or 3 carbon atoms in length; R1 is hydrogen; a carbocyclic or heterocyclic group having from 3 to 12 ring members; or a C1-8 hydrocarbyl group optionally substituted by one or more substituents selected from halogen, hydroxy, C1-4 hydrocarbyloxy, amino, mono- or di-C1-4 hydrocarbylamino, and carbocyclic or heterocyclic groups having from 3 to 12 ring members, and wherein 1 or 2 of the carbon atoms of the hydrocarbyl group may optionally be replaced by an atom or group selected from O, S, NH, SO, SO2; R2 is hydrogen; halogen; C1-4 alkoxy; or a C1-4 hydrocarbyl group optionally substituted by halogen, hydroxyl or C1-4 alkoxy; R3 is selected from hydrogen and carbocyclic and heterocyclic groups having from 3 to 12 ring members; and R4 is hydrogen or a C1-4 hydrocarbyl group optionally substituted by halogen, hydroxyl or C1-4 alkoxy.
摘要翻译：本发明提供包含辅助化合物和具有式（O）的化合物的组合：或其盐或互变异构体或N-氧化物或溶剂合物; 其中X为基团R 1 -A-NR 4 - 或5或6元碳环或杂环; A为键，SO 2，C-O，NR 9（C-O）或O（C-O），其中R 9为氢或任选被羟基或C 1-4烷氧基取代的C 1-4烃基; Y是长度为1,2或3个碳原子的键或亚烷基链; R1是氢; 具有3至12个环成员的碳环或杂环基; 或任选被一个或多个选自卤素，羟基，C 1-4烃氧基，氨基，一或二-C 1-4烃基氨基的取代基取代的C 1-8烃基，以及具有3-12个环成员的碳环或杂环基，并且其中所述烃基的1或2个碳原子可以任选地被选自O，S，NH，SO，SO 2的原子或基团取代; R2是氢; 卤素; C 1-4烷氧基; 或任选被卤素，羟基或C 1-4烷氧基取代的C 1-4烃基; R 3选自具有3至12个环成员的氢和碳环和杂环基; R4是氢或任选被卤素，羟基或C 1-4烷氧基取代的C 1-4烃基。

7. 发明申请

US20090082370A1 Pharmaceutical Combinations of PK Inhibitors and Other Active Agents 审中-公开
标题翻译： PK抑制剂和其他活性剂的药物组合
公开(公告)号：US20090082370A1
公开(公告)日：2009-03-26
申请号：US12298286
申请日：2007-04-25
申请人： Neil Thomas Thompson , John Francis Lyons , Robert George Boyle , Kyla Merriom Grimshaw , Michelle Dawn Garrett , Ian Collins
发明人： Neil Thomas Thompson , John Francis Lyons , Robert George Boyle , Kyla Merriom Grimshaw , Michelle Dawn Garrett , Ian Collins
IPC分类号： A61K31/519 , C07D487/04 , A61P35/00
CPC分类号： A61K45/06 , A61K31/52 , A61K31/5377 , A61K2300/00
摘要： The invention provides a combination for use as a protein kinase B inhibitor, the combination comprising (or consisting essentially of) an ancillary compound and: (I) a compound of the formula: or salts, solvates, tautomers or N-oxides thereof, wherein R1, Q1, Q2, E, G, T, R4, J1 and J2 are as defined in the claims; or (II) a compound having the formula (I): or salts, solvates, tautomers or N-oxides thereof, wherein R1, R2, R3, R4, E, A, T, J1 and J2 are as defined in the claims.
摘要翻译：本发明提供了用作蛋白激酶B抑制剂的组合，所述组合包含（或由其基本上由）辅助化合物组成，和：（I）下式化合物或其盐，溶剂合物，互变异构体或N-氧化物，其中 R1，Q1，Q2，E，G，T，R4，J1和J2如权利要求中所定义; 或（II）具有式（I）的化合物：或其盐，溶剂化物，互变异构体或N-氧化物，其中R1，R2，R3，R4，E，A，T，J1和J2如权利要求中所定义。

8. 发明授权

US08883790B2 Pharmaceutical combinations 有权
标题翻译：药物组合
公开(公告)号：US08883790B2
公开(公告)日：2014-11-11
申请号：US12445136
申请日：2007-10-12
申请人： Neil James Gallagher , John Francis Lyons , Neil Thomas Thompson , Stephen Murray Yule , Christopher William Murray
发明人： Neil James Gallagher , John Francis Lyons , Neil Thomas Thompson , Stephen Murray Yule , Christopher William Murray
IPC分类号： A61K31/497 , A61K31/535 , C07D401/14 , A61K31/403 , A61K31/438 , A61K31/439 , C07D209/08 , C07D209/44 , C07D215/08 , C07D401/04 , C07D471/04 , C07D471/10 , C07D491/08 , C07D491/10 , A61K31/496 , A61K31/5375
CPC分类号： C07D401/14 , A61K31/403 , A61K31/438 , A61K31/439 , A61K31/496 , A61K31/5375 , C07D209/08 , C07D209/44 , C07D215/08 , C07D401/04 , C07D471/04 , C07D471/10 , C07D491/08 , C07D491/10 , A61K2300/00
摘要： The invention provides combinations comprising (or consisting essentially of) one or more ancillary compound(s) and a compound of the formula (I): or salts, tautomers, solvates and N-oxides thereof; wherein R1 is hydroxy or hydrogen; R2 is hydroxy; methoxy or hydrogen; provided that at least one of R1 and R2 is hydroxy; R3 is selected from hydrogen; halogen; cyano; optionally substituted C1-5 hydrocarbyl and optionally substituted C1-5 hydrocarbyloxy; R4 is selected from hydrogen; a group —(O)n—R7 where n is 0 or 1 and R7 is an optionally substituted acyclic C1-5 hydrocarbyl group or a monocyclic carbocyclic or heterocyclic group having 3 to 7 ring members; halogen; cyano; hydroxy; amino; and optionally substituted mono- or di-C1-5 hydrocarbyl-amino; or R3 and R4 together form a monocyclic carbocyclic or heterocyclic ring of 5 to 7 ring members; and NR5R6 forms an optionally substituted bicyclic heterocyclic group having 8 to 12 ring members of which up to 5 ring members are heteroatoms selected from oxygen, nitrogen and sulphur. The combinations have activity as Hsp90 and/or glycogen synthase kinase-3 and/or cyclin dependent kinase and/or aurora kinase inhibitors.
摘要翻译：本发明提供包含（或基本上由）一种或多种辅助化合物和式（I）化合物或其盐，互变异构体，溶剂合物和N-氧化物的组合; 其中R1是羟基或氢; R2是羟基; 甲氧基或氢; 条件是R 1和R 2中的至少一个是羟基; R3选自氢; 卤素; 氰基; 任选取代的C 1-5烃基和任选取代的C 1-5烃氧基; R4选自氢; 其中n为0或1，R7为任选取代的无环C 1-5烃基或具有3至7个环成员的单环碳环或杂环基团 - （O）n -R 7基团; 卤素; 氰基羟基; 氨基; 和任选取代的单或二-C 1-5烃基 - 氨基; 或R 3和R 4一起形成5至7个环成员的单环碳环或杂环; 并且NR 5 R 6形成具有8至12个环成员的任选取代的双环杂环基，其中多达5个环成员是选自氧，氮和硫的杂原子。这些组合具有作为Hsp90和/或糖原合酶激酶-3和/或细胞周期蛋白依赖性激酶和/或极光激酶抑制剂的活性。

9. 发明授权

US08541461B2 Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators 失效
标题翻译：包含吡唑衍生物作为蛋白激酶调节剂的药物组合
公开(公告)号：US08541461B2
公开(公告)日：2013-09-24
申请号：US11993823
申请日：2006-06-21
申请人： Neil Thomas Thompson , Robert George Boyle , Ian Collins , Michelle Dawn Garrett , John Francis Lyons , Kyla Merriom Thompson
发明人： Neil Thomas Thompson , Robert George Boyle , Ian Collins , Michelle Dawn Garrett , John Francis Lyons , Kyla Merriom Thompson
IPC分类号： A61K31/415
CPC分类号： A61K45/06 , A61K31/415 , A61K31/454 , A61K2300/00
摘要： The invention provides a combination comprising an ancillary compound (e.g. one, two or more ancillary compounds) and a compound of the formula (I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R1 and NR2R3 and a maximum chain length of 4 atoms extending between E and NR2R3, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the linker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom α with respect to the NR2R3 group and provided that the oxo group when present is located at a carbon atom α with respect to the NR2R3 group; E is a monocyclic or bicyclic carbocyclic or heterocyclic group; R1 is an aryl or heteroaryl group; and R2, R3, R4 and R5 are as defined in the claims. Also provided are patient packs, pharmaceutical kits and packs and compositions containing the combinations, methods for preparing the combinations and their use in combination therapy as anticancer agents.
摘要翻译：本发明提供包含辅助化合物（例如一种，两种或多种辅助化合物）和具有蛋白激酶B抑制活性的式（I）化合物的组合的组合：其中A是含有1至7个碳原子的饱和烃连接基团，连接基团具有在R1和NR2R3之间延伸的5个原子的最大链长度，以及在E和NR 2 R 3之间延伸的4个原子的最大链长度，其中连接基团中的一个碳原子可以任选被氧或氮取代原子; 并且其中连接基团A的碳原子可以任选地具有一个或多个选自氧代，氟和羟基的取代基，条件是当存在的羟基不相对于NR 2 R 3基团位于碳原子α时，条件是存在时的氧代基位于相对于NR 2 R 3基团的碳原子α; E是单环或双环碳环或杂环基; R1是芳基或杂芳基; 并且R 2，R 3，R 4和R 5如权利要求中所定义。还提供了包含组合的患者包装，药物盒和包装和组合，用于制备组合的方法及其在联合治疗中作为抗癌剂的用途。

10. 发明授权

US08404718B2 Combinations of pyrazole kinase inhibitors 有权
标题翻译：吡唑激酶抑制剂的组合
公开(公告)号：US08404718B2
公开(公告)日：2013-03-26
申请号：US12752772
申请日：2010-04-01
申请人： Jayne Elizabeth Curry , John Francis Lyons , Matthew Simon Squires , Neil Thomas Thompson , Kyla Merriom Thompson , Paul Graham Wyatt
发明人： Jayne Elizabeth Curry , John Francis Lyons , Matthew Simon Squires , Neil Thomas Thompson , Kyla Merriom Thompson , Paul Graham Wyatt
IPC分类号： A61K31/4465 , A61K31/4468 , A61K31/454 , C07D401/12
CPC分类号： A61K45/06 , A61K31/415 , A61K31/4439 , A61K31/497 , A61K33/24 , A61K2300/00
摘要： The invention provides a combination comprising a cytotoxic compound, a signalling inhibitor, an ancillary agent, or two or more further anti-cancer agents, and a compound having the formula (Ib): or salts or tautomers or N-oxides or solvates thereof; wherein X is a group R1-A-NR4—; A is a bond, C═O, NRg(C═O) or O(C═O) wherein Rg is hydrogen or C1-4 hydrocarbyl optionally substituted by hydroxy or C1-4 alkoxy; Y is a bond or an alkylene chain of 1, 2 or 3 carbon atoms in length; R1 is a carbocyclic or heterocyclic group having from 3 to 12 ring members; or a C1-8 hydrocarbyl group optionally substituted by one or more substituents selected from fluorine, hydroxy, C1-4 hydrocarbyloxy, amino, mono- or di-C1-4 hydrocarbylamino, and carbocyclic or heterocyclic groups having from 3 to 12 ring members, and wherein 1 or 2 of the carbon atoms of the hydrocarbyl group may optionally be replaced by an atom or group selected from O, S, NH, SO, SO2; R2 is hydrogen; halogen; C1-4 alkoxy (e.g. methoxy); or a C1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C1-4 alkoxy (e.g. methoxy); R3 is selected from carbocyclic and heterocyclic groups having from 3 to 12 ring members; and R4 is hydrogen or a C1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C1-4 alkoxy (e.g. methoxy).
摘要翻译：本发明提供了包含细胞毒性化合物，信号传导抑制剂，辅助剂或两种或更多种其它抗癌剂和具有式（Ib）的化合物或其盐或互变异构体或N-氧化物或溶剂合物的组合：其中X是基团R 1 -A-NR 4 - ; A是键，C = O，NR g（C = O）或O（C = O），其中R g是氢或任选被羟基或C 1-4烷氧基取代的C 1-4烃基; Y是长度为1,2或3个碳原子的键或亚烷基链; R1是具有3-12个环成员的碳环或杂环基; 或任选被一个或多个选自氟，羟基，C 1-4烃氧基，氨基，一或二-C 1-4烃基氨基的取代基取代的C 1-8烃基，以及具有3-12个环成员的碳环或杂环基，并且其中所述烃基的1或2个碳原子可以任选地被选自O，S，NH，SO，SO 2的原子或基团取代; R2是氢; 卤素; C 1-4烷氧基（如甲氧基）; 或任选被卤素（例如氟），羟基或C 1-4烷氧基（例如甲氧基）取代的C 1-4烃基; R3选自具有3至12个环成员的碳环和杂环基; 和R 4是氢或任选被卤素（例如氟），羟基或C 1-4烷氧基（例如甲氧基）取代的C 1-4烃基。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式